Deep Pharma Intelligence
The Rise of Advanced Technologies in the Pharmaceutical Industry
On November 15th - 17th 2021 Deep Pharma Intelligence (DPI) will host three virtual events that will focus on key industry trends, activities, and investing takeaways in the artificial intelligence (AI) in the Pharma sector. DPI is an outstanding provider of open source and proprietary analytics in the Pharmaceutical and AI in Pharma industry, and a joint venture formed between Deep Knowledge Group’s DeepTech-focused analytical subsidiary, Deep Knowledge Analytics, and Biopharma Trend.
A growing number of industry experts will present and discuss the increasing market maturation of the AI in Pharma space, from both a collaborative effort and alliance perspective, as well as financing, agreement, M&A, SPAC and IPO perspective at the conference "The Rise of Advanced Technologies in the Pharmaceutical Industry".
Disruptive technologies and emerging trends such as robotics, artificial intelligence, precision medicine, and patient design will have an impact on pharmaceutical manufacturing and distribution. Invited specialists and DKG professionals will give speeches regarding these arising tendencies and technologies in use.
Astounding advances in computational power, combined with advancements in AI technology, are revolutionizing the drug development process. At this event, on the one hand, we will discuss how AI improves the efficiency of drug development, as well as how pharmaceutical industry titans can collaborate with AI-powered drug discovery firms to sustain their drug development programs. On the other hand, the event will highlight big-tech companies' partnerships with drug discovery businesses.
Longevity and biotech industries are poised for a massive leap in the near future, owing to the impact of AI on biomedicine R&D and the impending paradigm shift from treatment to preventative measures. The final conference event will shed light on key observations in the rapidly evolving and exponentially growing Longevity Industry's private equity, venture capital ecosystem and SPACs.